EUCTR2020-001366-11-RO进行中（未招募）1 期
An international randomised trial of additional treatments for COVID-19 inhospitalised patients who are all receiving the local standard of care - Solidarity
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 100,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •consenting adults (age =18) hospitalised with definite COVID-19, not
- •already receiving any of the study drugs
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 200
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 800
排除标准
- •-known allergy or contra-indications to investigational products
- •-anticipated transfer within 72 hours to a non-study hospital.
研究者
相似试验
进行中（未招募）
1 期
An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of careEUCTR2020-001366-11-LVWorld Health Organization100,000
进行中（未招募）
1 期
An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of careCOVID-19EUCTR2020-001366-11-IEWorld Health Organisation100,000
进行中（未招募）
1 期
An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of careCOVID-19EUCTR2020-001366-11-ESFIB-HCSC100,000
进行中（未招募）
1 期
An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of careEUCTR2020-001366-11-SKMinisterstvo Zdravotníctva Slovenskej republiky100,000
进行中（未招募）
1 期
An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of careCOVID-19MedDRA version: 23.0Level: HLTClassification code 10084510Term: Coronavirus infectionsSystem Organ Class: 100000004862EUCTR2020-001366-11-PTAICIB100,000